The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders

Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,676

Memantine in Moderate-to-Severe Alzheimer's Disease

Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043

beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity

Mattson, M. P., Cheng, B., Davis, D. G., Bryant, K., Lieberburg, I. M., & Rydel, R. E. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00376.1992 · Cited by 1,633

The Time Course of Glutamate in the Synaptic Cleft

Clements, J. D., Lester, R. A. J., Tong, G., Jahr, C. E., & Westbrook, G. L. (1992) · Science · doi:10.1126/science.1359647 · Cited by 1,089

Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease.

Pearson, R. C., Esiri, M. M., Hiorns, R. W., Wilcock, G. K., & Powell, T. P. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.13.4531 · Cited by 987

Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data

Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 900

Staging of Alzheimer-Related Cortical Destruction

Braak, H., Braak, E., & Bohl, J. (2008) · European Neurology · doi:10.1159/000116984 · Cited by 836 · cited 2×

Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain

Moechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V. D., Checler, F., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6483 · Cited by 668

β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage

Koh, J., Yang, L. L., & Cotman, C. W. (1990) · Brain Research · doi:10.1016/0006-8993(90)91355-k · Cited by 617

Alternative excitotoxic hypotheses

Albin, R. L., & Greenamyre, J. T. (1992) · Neurology · doi:10.1212/wnl.42.4.733 · Cited by 574 · cited 1×

A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis

Harry, R. D., & Zakzanis, K. K. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.676 · Cited by 25

Management of moderate to severe Alzheimer’s disease: Focus on memantine

Dominguez, E., Chin, T., Chen, C., & Wu, T. (2011) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2011.10.004 · Cited by 25

Signaling Pathways Relevant to Cognition-Enhancing Drug Targets

Ménard, C., Gaudreau, P., & Quirion, R. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_3 · Cited by 24

Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimer’s Disease

Kumar, A., Sudevan, S. T., Nair, A. S., Singh, A. K., Kumar, S., Jose, J., Behl, T., Mangalathillam, S., Mathew, B., & Kim, H. (2023) · Brain Sciences · doi:10.3390/brainsci13020213 · Cited by 26

Memantine benefits functional abilities in moderate to severe Alzheimer's disease

Winblad, B. G., Gauthier, S. G., Åström, D. O., & Stender, K. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0122-x · Cited by 24

Pharmacological treatment in moderate-to-severe Alzheimer's disease

Hsiung, G. R., & Feldman, H. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.15.2575 · Cited by 24

Insulin‐like growth factor‐2 is a promising candidate for the treatment and prevention of Alzheimer's disease

Fitzgerald, G. S., Chuchta, T. G., & McNay, E. C. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14160 · Cited by 22

Metformin inhibits Aβ25‐35‐induced apoptotic cell death in SH‐SY5Y cells

Li, L., Liu, M., Jiang, X., Xia, Z., Wang, Y., An, D., Wang, H., Heng, B., & Liu, Y. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13279 · Cited by 24

Memantine (Ebixa®) in Clinical Practice – Results of an Observational Study

Calabrese, P., Essner, U., & Förstl, H. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000104872 · Cited by 23

NMDA receptor is involved in neuroinflammation in intracerebroventricular colchicine-injected rats

Sil, S., Ghosh, T., & Ghosh, R. (2016) · Journal of Immunotoxicology · doi:10.3109/1547691x.2015.1130760 · Cited by 24

Interaction of memantine with calf thymus DNA: an in-vitro and in-silico approach and cytotoxic effect on the cancerous cell lines

Ameen, F., Siddiqui, S., Kausar, T., Nayeem, S. M., Sarwar, T., Rizvi, M. M. A., Rehman, S. U., & Tabish, M. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1823886 · Cited by 22

Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease

Hsiung, G. R., & Puangthong, U. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5021 · Cited by 22

Memantine Inhibits α3β2-nAChRs-Mediated Nitrergic Neurogenic Vasodilation in Porcine Basilar Arteries

Lee, R. H., Tseng, T.-Y., Wu, C. Y., Chen, P., Chen, M., Kuo, J., & Lee, T. J.-F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040326 · Cited by 22

Formulation strategies for nose-to-brain drug delivery in Alzheimer's disease

Vohra, M., Amir, M., Sharma, A., & Wadhwa, S. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100075 · Cited by 21

Inhibition of Astrocytic Histamine N-Methyltransferase as a Possible Target for the Treatment of Alzheimer’s Disease

Flores‐Clemente, C., Nicolás‐Vázquez, M. I., Jiménez, E. M., & Rodríguez, M. H. (2021) · Biomolecules · doi:10.3390/biom11101408 · Cited by 21

Preliminary exploration of the co-regulation of Alzheimer’s disease pathogenic genes by microRNAs and transcription factors

Zhang, Q., Yang, P., Pang, X., Guo, W., Sun, Y., Wei, Y., & Pang, C.-Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1069606 · Cited by 20

Diagnosis and Management of the Patient with Suspected Dementia in Primary Care

Holzer, S., Warner, J. P., & Iliffe, S. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0098-4 · Cited by 19

Orally bioavailable small molecule drug protects memory in Alzheimer's disease models

O‘Hare, E., Scopes, D. I. C., Kim, E., Palmer, P., Jones, M. G., Whyment, A. D., Spanswick, D. C., Amijee, H., Nerou, E., McMahon, B., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.016 · Cited by 18

A Review of Glutamate Receptors II: Pathophysiology and Pathology

Rousseaux, C. G. (2008) · Journal of Toxicologic Pathology · doi:10.1293/tox.21.133 · Cited by 19

What Is the Rationale for New Treatment Strategies in Alzheimer's Disease?

Rogawski, M. A. (2004) · CNS Spectrums · doi:10.1017/s1092852900024743 · Cited by 19

Indanone: a promising scaffold for new drug discovery against neurodegenerative disorders

Bansal, R., Singh, R., Dutta, T. S., Dar, Z. A., & Bajpai, A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104063 · Cited by 18

Enhanced LTP in aged rats: Detrimental or compensatory?

Pinho, J., do Vale, R. D., Batalha, V. L., Costenla, A. R., Dias, R. B., Rombo, D. M., Sebastião, A. M., de Mendonça, A., & Diógenes, M. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.017 · Cited by 18

Memantine does not show intracellular block of the NMDA receptor channel

Parsons, C. G., Gilling, K. E., & Jatzke, C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.053 · Cited by 18

Saffron and its major constituents against neurodegenerative diseases: A mechanistic review

Abdian, S., Fakhri, S., Moradi, S. Z., Khirehgesh, M. R., & Echeverría, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156097 · Cited by 19

A Snapshot on the Current Status of Alzheimer’s Disease, Treatment Perspectives, in-Vitro and in-Vivo Research Studies and Future Opportunities

Tezel, G., Timur, S. S., Bozkurt, İ., Türkoğlu, Ö. F., Eroğlu, İ., Nemutlu, E., Öner, L., & Eroğlu, H. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00511 · Cited by 17

Computational Assessment and Pharmacological Property Breakdown of Eight Patented and Candidate Drugs against Four Intended Targets in Alzheimer’s Disease

Sarkar, B., Islam, S. S., Ullah, M. A., Hossain, S., Prottoy, M. N. I., Araf, Y., & Taniya, M. A. (2019) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2019.1011030 · Cited by 17

Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer’s Disease

Couly, S., Denus, M., Bouchet, M., Rubinstenn, G., & Maurice, T. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa075 · Cited by 19

The use of the hippocampal slice preparation in the study of Alzheimer's disease

Fitzjohn, S. M., Doherty, A. J., & Collingridge, G. L. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.077 · Cited by 20

Memantine increases brain production of kynurenic acid via protein kinase A-dependent mechanism

Kloc, R., Luchowska, E., Wielosz, M., Owe‐Larsson, B., & Urbańska, E. M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.02.027 · Cited by 17

Determination of memantine in human plasma by GC using negative ion chemical ionization MS detection after derivatization with a new reagent

Leis, H. J., & Windischhofer, W. (2012) · Microchimica Acta · doi:10.1007/s00604-012-0840-3 · Cited by 17

Memantine: An antiglutamatergic option for dementia

Molinuevo, J. L., Garcia-Gil, V., & Villar, A. (2004) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750401900103 · Cited by 17

Synthetic β-hydroxy ketone derivative inhibits cholinesterases, rescues oxidative stress and ameliorates cognitive deficits in 5XFAD mice model of AD

Ahmad, S. I., Ali, G., Muhammad, T., Ullah, R., Umar, M. N., & Hashmi, A. N. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05997-0 · Cited by 16

HSF1 and Its Role in Huntington’s Disease Pathology

Kim, H., & Gómez‐Pastor, R. (2022) · Advances in experimental medicine and biology · doi:10.1007/5584_2022_742 · Cited by 21

Functional in vitro characterization of CR 3394: A novel voltage dependent N-methyl-d-aspartate (NMDA) receptor antagonist

Losi, G., Lanza, M., Makovec, F., Artusi, R., Caselli, G., & Puia, G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.09.002 · Cited by 16

Effect of chronic administration of ketamine on the mitochondrial respiratory chain activity caused by chronic mild stress

Rezin, G. T., Gonçalves, C. L., Daufenbach, J. F., Carvalho‐Silva, M., Borges, L. S., Vieira, J. S., Hermani, F. V., Comim, C. M., Quevedo, J., & STRECK, E. L. (2010) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2010.00500.x · Cited by 16

Mecamylamine prevents neuronal apoptosis induced by glutamate and low potassium via differential anticholinergic-independent mechanisms

Fu, H., Dou, J., Li, W., Luo, J., Li, K. C., Lam, C. S. C., Lee, N. T. K., Li, M., & Han, Y. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.003 · Cited by 16

Natural Products as Bioactive Agents in the Prevention of Dementia

Rasool, M., Ullah, H., Hussain, A., Asif, M., & Nawaz, F. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220422085835 · Cited by 19

Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive– Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials

Kishi, T., Matsuda, Y., & Iwata, N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180237 · Cited by 15

Memantine Affects Cognitive Flexibility in the Morris Water Maze

Saab, B. J., Luca, R. M., Yuen, W. B., Saab, A. M. P., & Roder, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110650 · Cited by 15

Adamantane amine derivatives as dual acting NMDA receptor and voltage-gated calcium channel inhibitors for neuroprotection

Kadernani, Y., Zindo, F. T., Kapp, E., Malan, S. F., & Joubert, J. (2014) · MedChemComm · doi:10.1039/c4md00244j · Cited by 15

Neuroprotection against excitotoxic and ischemic insults by bis(12)-hupyridone, a novel anti-acetylcholinesterase dimer, possibly via acting on multiple targets

Zhao, Y., Dou, J., Luo, J., Li, W., Chan, H. H. N., Cui, W., Zhang, H., Han, R., Carlier, P. R., Zhang, X., et al. (2011) · Brain Research · doi:10.1016/j.brainres.2011.09.014 · Cited by 15

Memantine, an NMDA receptor antagonist, improves working memory deficits in DGKβ knockout mice

Kakefuda, K., Ishisaka, M., Tsuruma, K., Shimazawa, M., & Hara, H. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.07.061 · Cited by 15

Add-on memantine may improve cognitive functions and attenuate inflammation in middle- to old-aged bipolar II disorder patients

Lu, R., Wang, T., Lee, S.-Y., Chang, Y.-H., Chen, S., Tsai, T.-Y., Chen, P. S., Huang, S., Tzeng, N., Lee, I. H., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.003 · Cited by 14

Pro-cognitive effects of dual tacrine derivatives acting as cholinesterase inhibitors and NMDA receptor antagonists

Chvojková, M., Kolář, D., Kovacova, K., Cejkova, L., Misiachna, A., Hakenova, K., Górecki, L., Hořák, M., Korábečný, J., Soukup, O., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116821 · Cited by 14

Senile Dementia from Neuroscientific and Islamic Perspectives

Tumiran, M. A., Rahman, N. N. A., Saat, R. M., Ismail, A. Z., Ruzali, W. A. W., Bashar, N. K. N., & Adli, D. S. H. (2015) · Journal of Religion and Health · doi:10.1007/s10943-015-0079-5 · Cited by 14

Effects of Nrf1 in Hypothalamic Paraventricular Nucleus on Regulating the Blood Pressure During Hypertension

Yu, X., Xiao, T., Liu, X.-J., Li, Y., Qi, J., Zhang, N., Fu, L., Liu, K., Li, Y., & Kang, Y. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.805070 · Cited by 14

Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801

Kato, T. (2004) · Folia Pharmacologica Japonica · doi:10.1254/fpj.124.145 · Cited by 14

Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study

Wroolie, T., Kenna, H. A., Williams, K. E., Powers, B. N., Holcomb, M. G., Lazzeroni, L. C., & Rasgon, N. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01084.x · Cited by 14

Glaucoma and Alzheimer’s Disease in the Elderly

Bizrah, M., Guo, L., & Cordeiro, M. F. (2011) · Aging Health · doi:10.2217/ahe.11.51 · Cited by 14

The fraction of activated N-methyl-d-Aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole

Rammes, G., Zieglgänsberger, W., & Parsons, C. G. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0059-y · Cited by 14

The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer’s Disease and Parkinson Disease

Gülcan, H. O., & Orhan, İ. E. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200131103524 · Cited by 14

Polymer drug conjugates containing memantine, tacrine and cinnamic acid: promising nanotherapeutics for the treatment of Alzheimer’s disease

Naki, T., Matshe, W. M. R., Balogun, M. O., Ray, S. S., Egieyeh, S. A., & Aderibigbe, B. A. (2023) · Journal of Microencapsulation · doi:10.1080/02652048.2023.2167011 · Cited by 14

Current Naturopathy to Combat Alzheimer’s Disease

Chakrovorty, A., Bhattacharjee, B., Saxena, A., Samadder, A., & Nandi, S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220927121022 · Cited by 13

Memantine attenuates the impairment of spatial learning and memory of pentylenetetrazol-kindled rats

Jia, L., Wang, W., Li, Z.-P., Zhen, J., An, L.-W., & Rui-sheng, D. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0561-0 · Cited by 13

Endogenous Kynurenic Acid and Neurotoxicity

Urbańska, E. M., Chmiel-Perzyńska, I., Perzyński, A., Derkacz, M., & Owe‐Larsson, B. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_92 · Cited by 13

A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists – in vitro characterization

Gilling, K. E., Jatzke, C., Wollenburg, C., Vanejevs, M., Kauss, V., Jirgensons, A., & Parsons, C. G. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0792-7 · Cited by 13

Influence of dizocilpine (MK-801) on neurotoxic effect of dexamethasone: Behavioral and histological studies

Danilczuk, Z., Sekita-Krzak, J., Lupina, T., Danilczuk, M., & Czerny, A. (2006) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2006-1609 · Cited by 13

Side Effects of Alzheimer's Disease Treatment

Pašti, T. D. L. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230112160522 · Cited by 12

Regional contributions of D-serine to Alzheimer’s disease pathology in male AppNL–G–F/NL–G–F mice

Ni, X., Inoue, R., Wu, Y., Yoshida, T., Yaku, K., Nakagawa, T., Saito, T., Saido, T. C., Takao, K., & Mori, H. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1211067 · Cited by 13

Potential Natural Products for Alzheimer’s Disease: Targeted Search Using the Internal Ribosome Entry Site of Tau and Amyloid-β Precursor Protein

Tasi, Y.-C., Chin, T., Chen, Y., Huang, C.-C., Lee, S.-L., & Wu, T. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16048789 · Cited by 12

Memantine misuse and social networks: A content analysis of Internet self‐reports

Natter, J., & Michel, B. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5070 · Cited by 12

Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from Xenopus oocytes

Parsons, C. G., Gilling, K. E., & Jatzke, C. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0087-7 · Cited by 12

Effects of Excitotoxic Lesion with Inhaled Anesthetics on Nervous System Cells of Rodents

Quiroz‐Padilla, M. F., Guillazo‐Blanch, G., Sánchez, M. Y., Domínguez‐Sánchez, M. A., & Gómez, R. M. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666170817125015 · Cited by 12

Microglial Sirtuin 2 Shapes Long-Term Potentiation in Hippocampal Slices

de Almeida, J. S., Vargas, M., Fonseca‐Gomes, J., Tanqueiro, S. R., Belo, R. F., Miranda‐Lourenço, C., Sebastião, A. M., Diógenes, M. J., & Pais, T. F. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00614 · Cited by 12

Harnessing memantine in Alzheimer's disease therapy through inhibition of microtubule affinity-regulating kinase: Mechanistic insights

Anwar, S., Choudhury, A., Hussain, A., Alajmi, M. F., Hassan, M. I., & Islam, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130090 · Cited by 11

Genomic stress and impaired DNA repair in Alzheimer disease

Neven, J., Issayama, L. K., Dewachter, I., & Wilson, D. M. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103678 · Cited by 12

Preparation and in vitro characterization of memantine HCl loaded PLGA nanoparticles for Alzheimer's disease

Tezel, G., Ulutürk, S., Reçber, T., Timur, S. S., Nemutlu, E., Esendağlı, G., Pınar, S. G., & Eroğlu, H. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106142 · Cited by 11

Allosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review

Silva, G. M., Barcelos, M. P., Poiani, J. G. C., Hage-Melim, L. I. D. S., & da Silva, C. H. T. D. P. (2019) · ChemMedChem · doi:10.1002/cmdc.201900299 · Cited by 12

Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer’s Disease, in Silico Trials

Świetlik, D., Białowas, J., Kusiak, A., & Krasny, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050546 · Cited by 11

Chemical similarity assisted search for acetylcholinesterase inhibitors: Molecular modeling and evaluation of their neuroprotective properties

Remya, C., Dileep, K. V., Variyar, E. J., Zhang, K. Y. J., Omkumar, R. V., & Sadasivan, C. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.148 · Cited by 11

Magnesium ions and dementia

Xu, P., Cui, D., Jin, M., & Sun, L. (2024) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2024.100094 · Cited by 12

Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease

Carles, A., Freyssin, A., Guehairia, S., Reguero, T., Vignes, M., Hirbec, H., Rubinstenn, G., & Maurice, T. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01648-9 · Cited by 12

Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer’s Disease

Yamalı, C., & Dönmez, Ş. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666221201145141 · Cited by 10

The effect of memantine on functional recovery of the sciatic nerve crush injury in rat

Ghayour, M.-B., Abdolmaleki, A., & Rassouli, M. B. (2016) · Turkish Neurosurgery · doi:10.5137/1019-5149.jtn.16792-15.1 · Cited by 10

Theoretical and Experimental Approaches Aimed at Drug Design Targeting Neurodegenerative Diseases

Morales-Navarro, S., Prent-Peñaloza, L., Rodríguez‐Núñez, Y. A., Sánchez-Aros, L., Forero‐Doria, O., González, W., Campillo, N. E., Reyes-Parada, M. I., Martı́nez, A., & Ramírez, D. (2019) · Processes · doi:10.3390/pr7120940 · Cited by 10

Nanomedicine: A New Frontier in Alzheimer’s Disease Drug Targeting

Pathak, K., Ahmad, M. Z., Saikia, R., Pathak, M. P., Sahariah, J. J., Kalita, P., Das, A., Islam, M. A., Pramanik, P., Tayeng, D., et al. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249281331240325042642 · Cited by 11

Neuroprotective strategies for NMDAR-mediated excitotoxicity in Huntington’s Disease

Girling, K., & Wang, Y. T. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1425-z · Cited by 9

Endogenous Kynurenic Acid and Neurotoxicity

Urbańska, E. M., Chmiel-Perzyńska, I., Perzyński, A., Derkacz, M., & Owe‐Larsson, B. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_92-1 · Cited by 9

Serendipitous improvement in the yips associated with memantine use

Ringman, J. M. (2007) · Movement Disorders · doi:10.1002/mds.21368 · Cited by 9

A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa® Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil (ROMEO-AD)

Kim, H.-J., Shim, Y., Han, H. J., Kim, B. C., Park, K. H., Moon, S. Y., Choi, S. H., Yang, D. W., Yoon, B., Kim, E., et al. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00494-5 · Cited by 9

Fluoroethylnormemantine (FENM) shows synergistic protection in combination with a sigma-1 receptor agonist in a mouse model of Alzheimer's disease

Freyssin, A., Carles, A., Guehairia, S., Rubinstenn, G., & Maurice, T. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109733 · Cited by 8

Locally Synthetized 17-β-Estradiol Reverses Amyloid-β-42-Induced Hippocampal Long-Term Potentiation Deficits

Bellingacci, L., Canonichesi, J., Sciaccaluga, M., Megaro, A., Mazzocchetti, P., Mauro, M. D., Costa, C., Filippo, M. D., Pettorossi, V. E., & Tozzi, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031377 · Cited by 7

Memantine: updates from the past decade and implications for future novel therapeutic applications

Danysz, W., Hansen, N., Wiltfang, J., Kornhuber, J., Scheschonka, A., & Gravius, A. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03017-8 · Cited by 7

Neuroanatomy/pathology and the interplay of neurotransmitters in moderate to severe Alzheimer disease

Francis, P. T. (2005) · Neurology · doi:10.1212/wnl.65.6_suppl_3.s5 · Cited by 7

Effects of positive modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors in a benzodiazepine-induced deficit of spatial discrimination in mice

Vandesquille, M., Carrié, I., Louis, C., Béracochéa, D., & Lestage, P. J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111416692 · Cited by 7

Exploring the neuroprotective role of Asparagus racemosus (Shatavari) in Alzheimer’s disease: mechanisms, evidence, and future directions

Nadeem, M., Khan, M. A., Ahmad, F. J., Parvez, S., Akhtar, M., & Najmi, A. K. (2025) · 3 Biotech · doi:10.1007/s13205-025-04355-w · Cited by 8

Unveiling Acid-Sensing Ion Channels (ASICs) in Neurodegeneration: Implications for Disease Pathogenesis and Therapeutic Strategies

Mohan, M., Mannan, A., & Singh, T. G. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00399-x · Cited by 6

Alzheimer's Disease: Focus on the Neuroprotective Role of Melatonin

Srinivasan, V., Lauterbach, E. C., Ahmed, A. H., & Prasad, A. (2012) · Journal of Neurology Research · doi:10.4021/jnr.v2i3.93 · Cited by 6

A Review on Current Strategies and Future Perspective in Respect to Alzheimer’s Disease Treatment

Bais, S., Kumari, R., & Prashar, Y. (2015) · Current Research in Neuroscience · doi:10.3923/crn.2016.1.15 · Cited by 6

Molecular Mimicry: Infection-Inducing Autoimmune Disease

Oldstone, M. B. A. (2005) · Current topics in microbiology and immunology · doi:10.1007/3-540-30791-5 · Cited by 6

Ion Channels – Ligand Gated

Briggs, C., & Gopalakrishnan, M. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00067-5 · Cited by 2

Involvement of the Serotonergic System in Cognitive and Behavioral Symptoms of Alzheimers Disease

Ramírez, M. J., Aisa, B., Gil-Bea, F. J., & Marcos, B. (2005) · Current Psychiatry Reviews · doi:10.2174/157340005774575073 · Cited by 6

Alzheimer’s disease and memantine effects on NMDA-receptor blockade: non-invasive in vivo insights from magnetoencephalography

Lanskey, J. H., Jafarian, A., Hughes, L. E., Karadag, M., Kocagöncü, E., Rouse, M. A., Adams, N., Naessens, M., Raymont, V., Woolrich, M. W., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03288-3 · Cited by 5

Recent Advances in Alzheimer’s Disease in Relation to Cholinesterase Inhibitors and NMDA Receptor Antagonists

Nazam, N., Farhana, A., & Shaikh, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-4558-7_8 · Cited by 5

ROCKs as a potential drug target to combat Alzheimer's disease

Ahmad, F., Rankawat, S., & Pathak, U. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00012-0 · Cited by 5

Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States

Aso, E., & Ferrer, I. (2013) · InTech eBooks · doi:10.5772/54783 · Cited by 5

Effect of Memantine on Overactive Detrusor in Rats With Spinal Cord Injury

Özkürkçügil, C., Kömür, O., & Özkan, L. (2010) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/s1607-551x(10)70036-x · Cited by 5

Ketamine Induces Rapid Onset of Antidepressant Action: Neurophysiological Biomarkers as Predictors of Effect

Quevedo, J., Comim, C. M., & Gavioli, E. C. (2009) · Biomarkers in Medicine · doi:10.2217/17520363.3.1.5 · Cited by 5

Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine

Chen, Y., Evola, M., & Young, A. M. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2807-9 · Cited by 5

Donepezil‐ or rivastigmine‐induced acetylcholinesterase inactivation is not modulated by neramexane in rat brain

Gupta, R. C., & Dekundy, A. (2007) · Drug Development Research · doi:10.1002/ddr.20186 · Cited by 5

Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action

Danysz, W., Parsons, C. G., Möbius, H. J., Stöffler, A., & Quack, G. (2000) · Neurotoxicity Research · doi:10.1007/bf03033787 · Cited by 262

Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease e an unified glutamatergic hypothesis on the mechanism of action

Danysz, W., Parsons, C., Möbius, H., Stöffler, A., & Quack, G. (2000)

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse

Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 724

NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer's therapy

(13455831), M. T. K., (15830342), M. S., (13455837), M. S. U., (13455840), M. M. B., (7724798), S. A., (9860528), A. I., (13377339), B. M., (13455843), M. S. I., (13455846), M. S. A., & (15815861), G. A. (2024) · Figshare · Cited by 2

Neuroprotección con memantina (antagonista no competitivo del receptor NMDA-glutamato) frente a la excitotoxicidad asociada al glutamato en la enfermedad de Alzheimer y en la demencia vascular

Tanovı́c, A., & Alfaro, V. (2006) · Revista de Neurología · doi:10.33588/rn.4210.2005252 · Cited by 32